PD1 blockade enhances K(+) channel activity, Ca(2+) signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer

BACKGROUND: Immunotherapy has emerged as a promising treatment modality for head and neck squamous cell carcinoma (HNSCC). Pembrolizumab, an anti-programmed death 1 antibody, is an immunotherapy agent currently approved for metastatic HNSCC and curative intent clinical trials. Although clinical resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Newton, Hannah S, Gawali, Vaibhavkumar S, Chimote, Ameet A, Lehn, Maria A, Palackdharry, Sarah M, Hinrichs, Benjamin H, Jandarov, Roman, Hildeman, David, Janssen, Edith M, Wise-Draper, Trisha M, Conforti, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566435/
https://www.ncbi.nlm.nih.gov/pubmed/33060146
http://dx.doi.org/10.1136/jitc-2020-000844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566435/
https://www.ncbi.nlm.nih.gov/pubmed/33060146
http://dx.doi.org/10.1136/jitc-2020-000844

Ejemplares similares